摘要
目的 探讨在人表皮生长因子受体2（human epidermal growth factor receptor2,HER2）过表达型乳腺癌新辅助化疗中血清HER2/neu浓度的变化及其与疗效的相关性.方法 采用酶联免疫法检测78例HER2过表达型局部进展期乳腺癌患者新辅助化疗前后血清HER2/neu的浓度,分析其变化与新辅助化疗疗效的相关性.结果 HER2过表达型乳腺癌患者新辅助化疗前后血清HER2/neu的浓度分别为（18.6±10.0） ng/ml,（11.6±6.1）ng/ml,前后比较差异有统计学意义（P ＜0.001）.新辅助化疗前后血清HER2/neu浓度变化与化疗疗效相关（P =0.029）.新辅助化疗前后血清HER2/neu浓度变化与病理完全缓解相关（P＜0.05）.结论 在HER2过表达型乳腺癌患者中,新辅助化疗前后血清HER2/neu浓度变化可作为预测化疗疗效的指标.
Objective To explore the change of serum HER2/neu concentration during neoadjuvant chemotherapy for HER2-overexpressed breast cancer and its correlation with the response to the neoadjuvant chemotherapy.Methods The concentration of the serum HER2/neu in 78 cases of HER2-overexpressed advanced breast cancer treated with neoadjuvant chemotherapy were detected with enzyme-linked immunosordent assay（ELISA）.The relationship between the serum HER2/neu concentration and the response of neoadjuvant chemotherapy was analyzed.Results The serum HER2/neu concentration of befor and after neoadjuvant chemotherapy was 18.6 ± 10.0ng/ml,11.6 ± 6.lng/ml respectively.The serum HER2/neu concentration decreased significantly（P ＜ 0.001）.The response of neoadjuvant chemotherapy was correlated with the change of the serum HER2/neu concentration.The pathologic complete response was correlated with the serum HER2/neu concentration of prechemotherapy and the change of the serum HER2/neu concentration.Conclusion The change of serum HER2/neu concentration may serve as a marker predicting the response of neoadjuvant chemotherapy in HER2-overexpressed breast cancer.
出处
《中华内分泌外科杂志》
CAS
2013年第5期368-370,383,共4页
Chinese Journal of Endocrine Surgery
基金
江苏省第四期＂333工程＂科研项目资助（BRA201114）
